Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
An update from Cybin ( (TSE:CYBN) ) is now available.
Cybin Inc. announced it will release its second quarter financial results and provide a business update on November 13, 2025, through a conference call and webcast. This announcement highlights Cybin’s ongoing efforts to advance its clinical programs and strengthen its position in the mental healthcare industry, potentially impacting stakeholders by showcasing its progress and financial health.
The most recent analyst rating on (TSE:CYBN) stock is a Buy with a C$150.00 price target. To see the full list of analyst forecasts on Cybin stock, see the TSE:CYBN Stock Forecast page.
Spark’s Take on TSE:CYBN Stock
According to Spark, TipRanks’ AI Analyst, TSE:CYBN is a Underperform.
Cybin’s stock score is significantly impacted by its lack of revenue and continuous financial losses, resulting in a low valuation score. While technical indicators are neutral, positive corporate events indicate potential for future growth. However, current financial challenges remain the dominant concern.
To see Spark’s full report on TSE:CYBN stock, click here.
More about Cybin
Cybin is a Phase 3 clinical-stage neuropsychiatry company focused on revolutionizing mental healthcare through innovative drug discovery platforms and delivery systems. The company is developing novel treatments for mental health conditions, including CYB003 for major depressive disorder and CYB004 for generalized anxiety disorder, with operations in Canada, the United States, the United Kingdom, and Ireland.
Technical Sentiment Signal: Hold
Current Market Cap: C$1.97M
For an in-depth examination of CYBN stock, go to TipRanks’ Overview page.